Dianthus Therapeutics, Inc. (DNTH)Healthcare | Biotechnology | New York, United States | NasdaqCM
70.82 USD
-3.71
(-4.978%) ⇩
(Oct. 16, 2026, 1:05 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 10:25 a.m. EDT
Dianthus Therapeutics presents a classic biotech dilemma: a fortress balance sheet masking a lack of commercial scale. The company sits on nearly $900 million in cash against negligible debt, giving it ample runway to fund its pipeline without immediate dilution. Yet, the stock has lost over three-quarters of its value over the past seven years, a stark reminder of the graveyard that lies ahead for unproven therapies. While analysts are screaming 'Strong Buy' based on the upcoming Phase 3 trial, the price action tells a different story, dropping 16% in just two weeks as investors digest the risk of failure. The recent recovery in annual returns is encouraging, but the cumulative drag remains severe. For now, this is a speculative hold rather than a core investment; the cash pile provides a safety net, but the business model has yet to prove it can generate sustainable profits beyond the lab. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.057203 |
| MSTL | 0.057534 |
| AutoARIMA | 0.057587 |
| AutoTheta | 0.064320 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 1.96 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.001 |
| Excess Kurtosis | 1.14 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.11 |
| Revenue per Share | 0.041 |
| Market Cap | 3,871,462,656 |
| Forward P/E | -15.36 |
| Beta | 0.18 |
| Website | https://dianthustx.com |
As of Oct. 10, 2026, 10:25 a.m. EDT: Speculators are positioning for a range-bound outcome between $60 and $100 over the next year. Near-term expiration shows elevated implied volatility with open interest clustering around the current price ($80-$90), suggesting hedging against further drops. However, the January 2027 call wall at the $100 strike indicates a bullish thesis for a recovery to the upper end of the 52-week range, while deep out-of-the-money puts suggest a tail-risk hedge against a deeper collapse.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0906031 |
| Address1 | 7 Times Square |
| Address2 | 43rd Floor |
| All Time High | 336.0 |
| All Time Low | 5.12 |
| Ask | 90.79 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 909,170 |
| Average Daily Volume3 Month | 803,464 |
| Average Volume | 803,464 |
| Average Volume10Days | 909,170 |
| Beta | 0.181 |
| Bid | 52.65 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 21.388 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 70.82 |
| Current Ratio | 26.1 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 75.3435 |
| Day Low | 70.25 |
| Debt To Equity | 0.11 |
| Display Name | Dianthus Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -217,720,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -15.08 |
| Enterprise To Revenue | 1,724.403 |
| Enterprise Value | 3,283,263,232 |
| Eps Current Year | -3.81404 |
| Eps Forward | -4.61098 |
| Eps Trailing Twelve Months | -4.24 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 100.0746 |
| Fifty Day Average Change | -29.2546 |
| Fifty Day Average Change Percent | -0.29232794 |
| Fifty Two Week Change Percent | 109.06031 |
| Fifty Two Week High | 117.88 |
| Fifty Two Week High Change | -47.059998 |
| Fifty Two Week High Change Percent | -0.39921954 |
| Fifty Two Week Low | 32.22 |
| Fifty Two Week Low Change | 38.6 |
| Fifty Two Week Low Change Percent | 1.1980135 |
| Fifty Two Week Range | 32.22 - 117.88 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,529,587,800,000 |
| Float Shares | 55,849,917 |
| Forward Eps | -4.61098 |
| Forward P E | -15.358991 |
| Free Cashflow | -92,210,496 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 92 |
| Fullday Change | -3.709999 |
| Fullday Change Percent | -4.97786 |
| Fullday Price | 70.82 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 1.0 |
| Gross Profits | 1,904,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00124 |
| Held Percent Institutions | 1.28671 |
| Implied Shares Outstanding | 54,666,233 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. |
| Long Name | Dianthus Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 3,871,462,656 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_631649032 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -192,246,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,222,033,530 |
| Number Of Analyst Opinions | 15 |
| Open | 74.41 |
| Operating Cashflow | -155,375,008 |
| Operating Margins | -80.79106 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 929 999 4055 |
| Previous Close | 74.53 |
| Price Eps Current Year | -18.568237 |
| Price Hint | 2 |
| Price To Book | 3.3112025 |
| Price To Sales Trailing12 Months | 2,033.3312 |
| Profit Margins | 0.0 |
| Quick Ratio | 25.791 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.05882 |
| Region | US |
| Regular Market Change | -3.709999 |
| Regular Market Change Percent | -4.97786 |
| Regular Market Day High | 75.3435 |
| Regular Market Day Low | 70.25 |
| Regular Market Day Range | 70.25 - 75.3435 |
| Regular Market Open | 74.41 |
| Regular Market Previous Close | 74.53 |
| Regular Market Price | 70.82 |
| Regular Market Time | 1,792,170,339 |
| Regular Market Volume | 294,053 |
| Return On Assets | -0.1769 |
| Return On Equity | -0.26065 |
| Revenue Growth | 2.943 |
| Revenue Per Share | 0.041 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 54,666,233 |
| Shares Percent Shares Out | 0.1634 |
| Shares Short | 9,140,581 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 8,429,902 |
| Short Name | Dianthus Therapeutics, Inc. |
| Short Percent Of Float | 0.1875 |
| Short Ratio | 10.65 |
| Source Interval | 15 |
| State | NY |
| Symbol | DNTH |
| Target High Price | 200.0 |
| Target Low Price | 122.0 |
| Target Mean Price | 140.8 |
| Target Median Price | 134.0 |
| Total Cash | 886,812,992 |
| Total Cash Per Share | 15.855 |
| Total Debt | 1,287,000 |
| Total Revenue | 1,904,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.24 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 82.9027 |
| Two Hundred Day Average Change | -12.082703 |
| Two Hundred Day Average Change Percent | -0.14574558 |
| Type Disp | Equity |
| Volume | 294,053 |
| Website | https://dianthustx.com |
| Zip | 10,036 |